Pergolide Treatment and Valvular Heart Disease
Information source: Århus Amt
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Valve Diseases; Parkinson's Disease; Pergolide; Fibrosis
Phase: N/A
Status: Completed
Sponsored by: Århus Amt Official(s) and/or principal investigator(s):
Vibeke G Rasmussen, MD, Principal Investigator, Affiliation: Skejby Hospital
Summary
In a blinded echocardiographic study we investigate the frequency of valvular abnormalities
in a group of Parkinson patients treated with either ergot derived dopamine agonists
(pergolide and cabergoline) or non-ergot derived dopamine agonists (pramipexole and
ropinirole). The ability to detect patients with valvular abnormalities by clinical approach
is examined.
Clinical Details
Study design: Screening, Cross-Sectional, Defined Population, Retrospective/Prospective Study
Detailed description:
Some case reports and a single study, which included 78 Parkinson patients, has found a
correlation between treatment with the ergotamine derivative dopamine agonists (pergolide)
and restrictive valvular heart disease. The mechanisms are thought to be the same as with the
former used anorectikum, fenfluramine and other drugs stimulating the 5HT-2B receptor.
In a blinded manner we make physiologic and echocardiographic examination on 160 Parkinson
patients treated with either ergotamine or non-ergotamine derivative dopamine agonists (80
patients in each group) to see whether Parkinson patients treated with ergotamine derivatives
have more heart valvular disease
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Parkinson patients who in the last year has been treated minimum 6 months with either
ergotamine derivative or non-ergotamine derivative dopamine agonists (the latter
included as controls)
- Informed contests
Exclusion Criteria:
- Control patients will be excluded if the have been treated with ergotamine derivates
in the last 12 months or if the prior to that have had ergotamine derivates for more
than 6 months
- Patients with known valvular heart disease prior to the diagnosis of Parkinson
Locations and Contacts
Skejby Hospital, Aarhus, Aahus N 8200, Denmark
Additional Information
Starting date: March 2005
Ending date: September 2007
Last updated: September 19, 2007
|
